Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice by de, Munter, J. P. J. M. et al.
504  |    CNS Neurosci Ther. 2020;26:504–517.wileyonlinelibrary.com/journal/cns
 
Received: 18 July 2019  |  Revised: 20 November 2019  |  Accepted: 22 November 2019
DOI: 10.1111/cns.13280  
O R I G I N A L  A R T I C L E
Neuro-Cells therapy improves motor outcomes and suppresses 
inflammation during experimental syndrome of amyotrophic 
lateral sclerosis in mice
Johannes P.J.M. de Munter1  |   Igor Shafarevich2  |   Alexei Liundup3  |    
Dmitrii Pavlov1,2,4  |   Erik Ch Wolters1  |   Anna Gorlova1,2  |   Ekaterina Veniaminova1,2  | 
Aleksei Umriukhin2  |   Allan Kalueff5,6  |   Andrei Svistunov2,3  |   Boris W. Kramer7  |   
Klaus-Peter Lesch1,2,8  |   Tatyana Strekalova1,2,4,8
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2019 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd
1Department of Psychiatry and 
Neuropsychology, School for Mental Health 
and Neuroscience, Maastricht University, 
Maastricht, The Netherlands
2Laboratory of Psychiatric Neurobiology, 
Institute of Molecular Medicine and 
Department of Normal Physiology, 
Sechenov First Moscow State Medical 
University, Moscow, Russia
3Institute of Regenerative Medicine, 
Sechenov First Moscow State Medical 
University, Moscow, Russia
4Laboratory of Cognitive Dysfunctions, 
Institute of General Pathology and 
Pathophysiology, Moscow, Russia
5Faculty of Biology, Ural Federal University, 
Ekaterinburg, Russia
6School of Pharmacy, Southwest University, 
Chongqing, China
7Department of Pediatrics, University 
Medical Center (MUCM), Maastricht, The 
Netherlands
8Division of Molecular Psychiatry, Center 
of Mental Health, University of Würzburg, 
Würzburg, Germany
Correspondence
Tatyana Strekalova, Dept. of Psychiatry and 
Neuropsychology, Maastricht University, 
Universiteitssingel 40, NL 6229 ER 
Maastricht, The Netherlands.
Email: t.strekalova@maastrichtuniversity.nl
Boris W. Kramer, Department of Pediatrics, 
University Medical Center (MUCM), P. 
Debyelaan 25, 229 HX Maastricht,  
Abstract
Aims: Mutations in DNA/RNA-binding factor (fused-in-sarcoma) FUS and superoxide 
dismutase-1 (SOD-1) cause amyotrophic lateral sclerosis (ALS). They were reproduced 
in SOD-1-G93A (SOD-1) and new FUS[1-359]-transgenic (FUS-tg) mice, where inflam-
mation contributes to disease progression. The effects of standard disease therapy 
and anti-inflammatory treatments were investigated using these mutants.
Methods: FUS-tg mice or controls received either vehicle, or standard ALS treatment 
riluzole (8 mg/kg/day), or anti-inflammatory drug a selective blocker of cyclooxyge-
nase-2 celecoxib (30 mg/kg/day) for six weeks, or a single intracerebroventricular 
(i.c.v.) infusion of Neuro-Cells (a preparation of 1.39 × 106 mesenchymal and he-
mopoietic human stem cells, containing 5 × 105 of CD34+ cells), which showed anti-
inflammatory properties. SOD-1 mice received i.c.v.-administration of Neuro-Cells or 
vehicle.
Results: All FUS-tg-treated animals displayed less marked reductions in weight gain, 
food/water intake, and motor deficits than FUS-tg-vehicle-treated mice. Neuro-Cell-
treated mutants had reduced muscle atrophy and lumbar motor neuron degeneration. 
This group but not celecoxib-FUS-tg-treated mice had ameliorated motor perfor-
mance and lumbar expression of microglial activation marker, ionized calcium-binding 
adapter molecule-1 (Iba-1), and glycogen-synthase-kinase-3ß (GSK-3ß). The Neuro-
Cells-treated-SOD-1 mice showed better motor functions than vehicle-treated-
SOD-1 group.
Conclusion: The neuropathology in FUS-tg mice is sensitive to standard ALS treat-
ments and Neuro-Cells infusion. The latter improves motor outcomes in two ALS 
models possibly by suppressing microglial activation.
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1  | INTRODUC TION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease 
characterized by progressive degeneration of lower motor neurons, 
as well as neurons in the cortex and brainstem, which leads to paral-
ysis and premature death.1 The etiology of ALS remains unclear both 
in sporadic cases (90%) and in the familial forms of ALS.1,2 Among 
the known genetic causes that give rise to ALS, the mutation of the 
fused in sarcoma protein (FUS) is the second most frequent among 
the familial forms of ALS.2-4
Mutations of FUS gene were thought to cause synaptic dys-
function and pathological protein aggregation,5 which were felt 
to be key events leading to neuronal degeneration.6 However, the 
most recent studies have revealed that the expression of mutant 
FUS leads to stress-mediated induction of chaperones, decreased 
expression of ion channels and transporters essential for synaptic 
function, and reduced synaptic activity without the loss of nuclear 
FUS or its cytoplasmic aggregation.7 The nuclear effects of FUS 
also seem to result in impairment of the function of paraspeck-
les, granules in the nuclear interchromatin space that are assem-
bled on a scaffold long noncoding RNA (lncRNA) NEAT1.8-10 This 
results in aberrant microRNA biogenesis, apoptotic processes, 
oxidative stress, and mitochondrial dysfunction contributing to 
neurodegenerative processes.9,10 Indeed, the latest studies using 
human fibroblast cell lines expressing mutant FUS from ALS pa-
tients and postmortem tissue have identified the accumulation of 
dysfunctional paraspeckles associated with abnormal NEAT1 ex-
pression as an important feature of FUS-associated ALS pathol-
ogy.11 NEAT1 was recently reported to promote inflammation via 
stimulating interleukin-1β production and pyroptosis and activat-
ing macrophages.12,13
Regardless of whether the disease is associated with FUS gene 
mutations or related to other factors, its pathological mechanisms 
are associated with neuroinflammation.1,2,4,14 In particular, the ac-
tivation of microglia and astrocytes is considered to be a hallmark 
of the disease and is accompanied by elevated pro-inflammatory 
cytokine concentrations in the brain, blood, and cerebrospinal 
fluid.14-16 For example, a recent clinical study reported high blood 
concentrations of pro-inflammatory cytokines and related pro-
teins in ALS patients, including interleukin-1β (IL-1β), interleukin 
6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor (TNF), and TNF 
receptor-1.17 It has been suggested that microglial inflammatory 
processes might be a key early event that contribute to neurode-
generation and play a dynamic role in the pathogenesis of the dis-
ease.14,16 Cerebrospinal fluid from ALS patients induces marked 
microglial activation, and upregulation of the pro-inflammatory 
cytokines and factors including IL-6, TNF, cyclooxygenase-2 
(COX-2), and prostaglandin E2 (PGE2), accompanied by a down-
regulation of trophic factors.15,18
Despite the evidence that the level of inflammation is critical 
in ALS, clinical studies with compounds that target inflammatory 
mechanisms and associated cascades, including the TNF inhibitor 
thalidomide, nonsteroid anti-inflammatory drugs (NSAIDs), a selec-
tive COX-2 inhibitor celecoxib, corticosteroids, cyclophosphamide, 
cyclosporine, cytochrome C inhibitors, and caspase-reducing drugs 
have all failed to induce significant improvement of the ALS pathol-
ogy.19-21 Thus, while the therapeutic niche for anti-inflammatory 
treatment of the ALS is strongly implicated by clinical and preclin-
ical studies, current literature lacks any clear examples of positive 
results.
In the present study, we sought to test the effects of a stem 
cell therapy “Neuro-Cells” with anti-inflammatory actions22,23 on 
experimental models of ALS in mice. Therefore, we have employed 
a FUS[1-359]-tg mouse model9 according to the guidelines set by 
Ludolph et al, 2010, for ALS preclinical studies24 that have recom-
mended the use of other ALS models apart from the SOD-1 mouse 
“gold standard”.25 The pattern of pathology in FUS[1-359]-tg line 
recapitulates key features of human ALS, including motor neuron 
degeneration and microgliosis in the brainstem and spinal cord, 
muscle atrophy, paralysis, microglial activation, and elevated lev-
els of pro-inflammatory cytokines in the CNS and blood.9,26-28 The 
model permits the impact of therapy on ALS-related changes to 
be evaluated including basic physiological and motor functions, 
as well as evaluation of the expression of pro-inflammatory and 
degeneration markers such as Iba-1, GSK-3ß, IL-1ß, and IL-6 in the 
lumbar spinal cord and blood levels of IL-1ß and IL-6. In the FUS 
model, the effect of the standard therapies has not been studied. 
We therefore chose to compare them to Neuro-Cells. In addition, 
we examined the effects of Neuro-Cells administration on motor 
function in the SOD-1 mouse line, a well-established model of ALS 
(G93A line;25).
Here, we gave in both models a single inracerebroventricular 
(i.c.v.) infusion of a preparation of nonmanipulated human stem cells 
“Neuro-Cells” obtained from bone marrow, which are a combination 
of both mesenchymal stem cells (MSCs) and hemopoietic stem cells 
(HSCs). As both MSCs and HSCs have been shown to have the abil-
ity to differentiate into a spectrum of adult cell populations, many 
studies have sought to examine either the combined or individual 
contributions to repair in vivo in models of injury and potentially 
capitalize on the relationship between the two cell populations that 
is known to exist.29,30 As for instance, MSCs were shown to act as a 
feeder layer maintaining HSCs in an undifferentiated state. If HSCs 
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are allowed to differentiate during their expansion, it increases the 
process of cell aging and death.31
In spinal injury models, the engraftment of CD34+ human HSCs 
produces neurons efficiently in the regenerating chicken embryo 
spinal cord32 and the use of MSCs to form guiding strands in the 
injured spinal cord promotes recovery.33 A direct comparison has 
been made between human mononuclear cell preparations (a mix-
ture of HSCs and MSCs) and culture-expanded MSCs transplanted 
into a spinal cord injury model in rats without differences with 
regard to graft efficiency, spinal cord tissue sparing, or glial scar 
reduction.34
In view of these results, we found that an injection of a mix-
ture of MSC and HSC, to maximize the potential benefit of these 
populations, had an anti-inflammatory effect.23 The intrathecal 
administration of the MSC/HSC preparation, containing 4 × 105 
of CD34+ cells into rats that had been subjected to a spinal cord 
injury, was shown to improve functional outcomes and decrease 
peripheral concentrations of pro-inflammatory cytokines (TNF, 
IL-1ß, and IL-6) in the cerebrospinal fluid.23 Previous studies have 
reported beneficial effects of stem cell therapy in animal models 
of ALS35-37; the majority of these studies employed manipulated 
MCSs,35,38-42 while the use of unmanipulated stem cells and prepa-
rations containing HSCs and MSCs has been shown to increase the 
therapeutic activity of stem cell therapy.41-43 Thus, we hypothe-
sized that this treatment might also ameliorate ALS-like pathology 
owing to the anti-inflammatory effects of Neuro-Cells. Here, we 
sought compare the effects of Neuro-Cells to the current anti-ALS 
therapy riluzole44 and the classic anti-inflammatory compound ce-
lecoxib45,46 in the new FUS-tg model.
2  | MATERIAL AND METHODS
Details on animals and all experimental procedures can be found in 
Data S1.
2.1 | Animals and human endpoint
FUS-tg, SOD-1 male mice and their wild-type littermates (WT) were 
provided by the FDA-certified IPAC RAS facilities and Charles River 
provider, respectively (http://www.ipac.ac. ru/index.html and http://
www.spf-anima ls.ru/about/ provi ders/animals). Mice were single 
housed under standard conditions and reversed lighting. Experimental 
procedures were set up in accordance with a Directive 2010/63/
EU and approved by the local veterinarian Committee for Bioethics 
of IPAC RAS (N19-16.06.2017) and MSMU (22/10/17-MSMU-35). 
Bone marrow collection from healthy volunteers was done under 
GMP license (Neuroplast BV Farmatec The Netherlands) and approved 
by Ethical Committee of MUMC, Maastricht University (iCell1 METC 
MUMC and iCell2 METC Zuyderland Zuid). All efforts were under-
taken to ensure compliance with above-mentioned regulations con-
cerning human endpoint in animal research.
2.2 | Study design
Experimental designs were based on reported patterns of pathology 
in employed models. ALS pathology in 12-week-old FUS-tg mutants is 
characterized by rapid, progressive motor neuron degeneration within 
2 weeks,9 while SOD-1 mouse line (G93A mutants) has more gradually 
developing ALS pathology displaying its first signs by the age of about 
16 weeks 25 progressing to the human endpoint within 4-6 weeks.47,48 
We devoted our efforts to ensure compliance with above-mentioned 
observations concerning human endpoint in animal research.
At the age of 7-8 weeks, FUS-tg animals and wild-type (WT) con-
trols were studied in a cat-walk, grip test, weighed (data not shown), 
and assigned to groups. At the age of nine weeks, FUS-tg and WT 
mice received (a) regular tap water, or (b) riluzole (Ril; 8 mg/kg/day, via 
drinking water), or (c) or celecoxib (Cel, 30 mg/kg/day) via food pellets, 
or (d) single i.c.v. administration of Neuro-Cells (NC, 500 000-CD34+ 
in 10 μL of Ringer Lactate buffer), or (d) i.c.v. administration of Ringer 
Lactate buffer (Figure 1A). Doses of pharmaca were selected as de-
scribed previously (49-51; see below). Stereotaxic surgery was adapted 
from previously reported procedure.52 During the following six weeks, 
all mice were weekly weighed and studied in the rotarod, pole, and 
wire tests for motor function, dosing with pharmaca was continued. As 
postsurgery physiological parameters of wild-type mice that received 
either tap water or i.c.v. vehicle injection were similar (Figure S1), these 
two groups were merged into a vehicle-treated (Veh) group for sub-
sequent analysis. On Week 6, at the age of fifteen weeks, mice were 
investigated for food and water intake and then sacrificed 24 hours 
thereafter. Mice were either perfused with NaCl or 4%-paraformalde-
hyde; muscle gastrocnemius, blood, and spinal cord were harvested 
for weighing, Western blot, ELISA assays, and histology. Since Neuro-
Cells-treated animals showed greater functional improvement than 
other groups, these mice and mutants subjected to the i.c.v. vehicle 
infusion were studied in all in vitro assays including muscle atrophy 
and motor neuron counts in the lumbar part of the spinal cord. The 
concentrations of IL-1ß and IL-6 in blood serum and protein expression 
of IL-1ß, IL-6, Iba-1, and GSK-3ß in the lumbar part of the spinal cord of 
mice treated with either vehicle, Neuro-Cells, or celecoxib were mea-
sured by ELISA and Western blot assays. Pharmaca outline and geno-
type were double blind for all experimenters. Numbers of animals used 
are indicated in Figure legends.
In additional experiment, SOD-1 male mice (G93A line) at age 
12 weeks were subjected to the i.c.v. infusion of the Neuro-Cells 
from the batch used in FUS-tg animals (SOD-1-NC group, n = 7) or to 
the i.c.v. vehicle administration (SOD-1-Veh group, n = 5; Figure 1B). 
Mice were weekly weighed and tested for motor functions for nine 
weeks as in a previous study and sacrificed at age of 21 weeks, at the 
onset of ALS-like syndrome in this model.25,47-49
2.3 | Functional readouts
Weekly measured body weights of mice were normalized to their 
baseline values recorded at week 1 (Figure 1). Body weights during 
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weeks 1-6 and weight gain between these weeks were normalized 
to the mean values of wild-type mice treated with vehicle (WT-Veh). 
On the 6th week, 24-hour food intake and 12-hour water intake 
were evaluated as described elsewhere.51
2.3.1 | Wire test
Mice were allowed to grip a horizontal wire (diameter 0.3 cm, height 
above the surface 60 cm) for 180s. The latency of falling and the 
number and percent of mice with falling events (latency < 20s) were 
recorded as described elsewhere.53
2.3.2 | Pole test
Mice were placed on a top of the vertical bar (diameter 1.1 cm, 
height 60 cm) and allowed to climb down to a horizontal surface. 
The latency of descending the bar and the number and percent of 
mice with sliding events (latency to descend < 50s) were scored as 
described elsewhere.53
2.3.3 | Rotarod
Mice were placed on constantly rotting rod of rotarod (Columbus 
Instruments, Columbus, OH, USA; speed 10 rpm) for 600s. Latency 
to fall and the number and percent of mice with falling events (la-
tency < 200s) were registered in three runs as described elsewhere.53
2.4 | Administration of drugs
In the study with FUS-tg mice, potential effects of Neuro-Cells 
were compared to effects of celecoxib, NSAID, and a COX-2 inhibi-
tor, that was used as a classic anti-inflammatory compound,45,46,50 
F I G U R E  1   Experiment design of study 
on (A) FUS-tg mice and (B) SOD-1 mice
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and of riluzole (2-amino-6-trifluoromethoxy-benzothiazole), a stand-
ard ALS treatment that can slow down the fatal disease progress by 
2-3 months44 and frequently serves as a reference drug in translational 
studies with ALS.47,49 Riluzole tablets (Sandoz, Almere, Netherlands) 
were crushed and dissolved in tap water, and its concentration was 
adjusted to the dosage of 8 mg/kg/day and daily water intake in CD1 
mice.47,49 elecoxib-containing food pellets were produced as described 
elsewhere,51 and drug concentration was adjusted to the dosage of 
30 mg/kg/day and daily diet consumption.
2.5 | Generation, properties, and 
intracerebroventricular infusion of Neuro-Cells
Neuro-Cells, a preparation of human bone marrow-derived HSCs and 
MSCs, was provided by Neuroplast BV (Maastricht, Netherlands). The 
Neuro-Cell preparation comprised 1.39 × 106 MSCs and HSCs, con-
taining 5 × 105 CD34+ cells in 10 μL. The expression profile of MSC 
markers was overlapping; in the total cell preparation 85.6% were 
CD105+, 13% were CD90+, 7% were CD271+, and 4% were CD73+ 
in single FACs staining. Prior to infusion, cells were resuspended and 
checked for vitality (see Data S1 and Table S2). Animals were anesthe-
tized by halothane (Halothane TM; Willy Rusch, Boblingen, Germany) 
and immobilized in a stereotaxic frame (World Precision Instruments, 
Sarasota, TX, USA) for unilateral i.c.v. infusion via a hole made in a 
scull of mice as described elsewhere.52 All preparations of Neuro-Cells 
were from the same stock sample. They were arranged ex temporo; 
after thawing, cell counting was performed using the “Countess II 
FL Automated Cell Counter” (Thermo Fisher Scientific AMQAF1000, 
Toronto, ON, Canada) showing 62%-68% cell vitality (see Data S1). 
Subsequent flow cytometry was done, and HSC numbers were ad-
justed for injection.
Pilot studies carried out to determine the distribution of infused 
Neuro-Cells and optimize the protocols for the i.c.v. administration, 
suggested their presence in the brain and peripheral organs 12 and 
24 hours after injection (100, 000 or 250, 000 cells were infused 
to lateral ventricles in 12 mice; see Data S1). Immunohistochemical 
study of Neuro-Cells-treated mice with human antimitochondrial 
antibodies was carried out as described elsewhere54 and revealed a 
positive signal in their ventricles, brain tissue, lungs, and spleen, sug-
gesting a wide distribution of Neuro-Cells in the cerebrospinal fluid 
and persistent vitality (see Data S1; Figures S1 and S2). These findings 
are consistent with the results of the pilot study with i.c.v. infusion of 
bone marrow-derived mouse stem cells obtained from mutants ex-
pressing green fluorescent protein (GFP) (see Data S1; Figure S3,55)
These experiments showed that i.c.v. administration of Neuro-Cells 
to mice at the concentrations 100 000-500 000 is well tolerated.
2.6 | Blood and tissue collection
Mice were terminally anesthetized by sodium pentobarbitone and 
from about a half of them, blood, both gastrocnemius muscles and 
lumbar parts of the spinal cord were collected as described else-
where.56 Another half was perfused with 4% paraformaldehyde; the 
lumbar parts of spinal cords and muscle gastrocnemius were dis-
sected as described elsewhere.56
2.7 | Scoring for muscle atrophy
Muscle gastrocnemius was fixed, sectioned, and stained for he-
matoxylin and eosin. Scoring for atrophy was performed by three 
independent pathologists, blinded to sample identity using a light 
microscope (Axiovision 4.3, Zeiss, Berlin, Germany); ranking his-
tograms were generated ranging samples were from 1 to 11 from 
“moderate” (1) to “severe” (11) atrophy.
2.8 | Motor neuron counting
Briefly, cross sections were carried out at 50-μm cuts encompassing 
L3-L5 with 250 μm interval and stained with thionine NISSL. Counts 
were performed by two observers blinded to sample identity using a 
Zeiss Axoplan2 system (Zeiss, Berlin, Germany).
2.9 | ELISA of plasma cytokines
Mouse enzyme-linked immunosorbent assay (ELISA) was per-
formed using MOUSE IL-1β and IL-6 ELISA MAX™ Deluxe Sets 
(BioLegend, San Diego, CA, USA) according to the manufacturer's 
instructions; protein concentrations were measured using the 
BCA protein assay kit (Pierce, Rockford, IL, USA) as described 
elsewhere.57
2.10 | Western blot and protein isolation
Western blot analysis on spinal cord samples and quantification 
of protein concentration were performed as described elsewhere 
(58; see Table S3). Relative expression of proteins was calculated in 
fold changes from levels of β-tubulin as described elsewhere.58 The 
Western blot images used for quantification are presented in Figure 
S6 and Appendix S1.
2.11 | Statistical analysis
GraphPad Prism 6.00 software (San Diego, CA, USA) was used; de-
pendently on groups, multiple group comparisons were analyzed 
using one-way, two-way, and repeated-measures ANOVA followed 
by the Tukey's test. Mann-Whitney test was used for two-group 
comparisons. Qualitative data were analyzed by Fisher's exact test. 
The level of significance was P < .05. The results are presented as 
bars with standard error of means (SEM).
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3  | RESULTS
3.1 | Physiological parameters in FUS-tg mice 
treated with riluzole, celecoxib, or Neuro-Cells
3.1.1 | Body weight, food, and liquid intake
Repeated-measures ANOVA and post hoc Tukey's tests revealed 
significant increases in body weight normalized to the basal val-
ues in WT-Veh, WT-Ril, and WT-Cel mice from week 1 to week 6 
(F3,29 = 7.86, P = .023; Figure 2A). FUS-tg-Veh mice displayed a sig-
nificant decrease in this measure (F3,29 = 12.76, P = .0147). No sig-
nificant changes in this parameter were found in FUS-tg mice that 
received either treatment (P > .05) indicating partial rescue effects 
of all applied treatments on FUS-tg mice.
Two-way ANOVA and post hoc Tukey's test revealed a signifi-
cant effect of genotype on body weight, normalized to the means 
of control mice at each week of study, at third to sixth weeks 
(P < .05, two-way ANOVA). This parameter was significantly lower 
in FUS-tg-Veh mice on the third to sixth weeks than in WT-Veh 
group (P = .031, P = .026, P = .018 and P = .001, respectively; 
Tukey's test, Figure S5). Such decreases were found in FUS-tg-Ril 
mice on the sixth week (P = .043) and in FUS-tg-Cel group, on the 
fifth and sixth weeks (P = .025 and P = .019, respectively), but not 
in FUS-tg-NC animals.
ANOVA showed significant effects of genotype and treatment 
for body weight gain (F1,10 = 27.98, P < .0001, and F3,10 = 3.499, 
P = .0182), but not for their interaction (F3,10 = 0.7239, P = .53499). 
There was a significant decrease in body weight gain in FUS-tg-
Veh, FUS-tg-Ril, and FUS-tg-Cel groups, but not in FUS-tg-NC ani-
mals, in comparison with controls (F2,15 = 4.6, P = .012; F2,7 = 18.39, 
P = .0068; F2,8 = 9.27, P < .005; F2,19 = 1.06, P = .599; respectively, 
Tukey's test, Figure 2B). FUS-tg-NC did not differ significantly 
from FUS-tg-Veh animals in this measure (F2,11 = 2.59, P = .1827). At 
Week 6, ANOVA showed significant effects of genotype and treat-
ment for body weight (F1,10 = 27.98, P < .0001, and F3,10 = 3.499, 
P = .0182), but not for their interaction (F3,10 = 0.7239, P = .53499). 
FUS-tg-Veh animals showed a significant decrease in body weight in 
comparison with WT-Veh group (F2,15 = 34.72, P = .015, Figure 2C) 
that was not observed in FUS-tg-treated groups (P > .05).
ANOVA revealed significant genotype effect for liquid intake 
(F1,57 = 11.78, P = .0011), but not treatment and a tendency to signif-
icance in their interaction (F3,57 = 0.6534, P = .5841 and F3,57 = 2.404, 
P = .0769). There was significant genotype effect for food intake 
(F1,71 = 10.58, P = .0018), but not treatment effect, nor their interac-
tion (F3,71 = 1.192, P = .3189, and F3,71 = 1.136, P = .3404). In compari-
son with WT-Veh group, both parameters were significantly decreased 
in FUS-tg-Veh mice (food intake: F2,29 = 10, P = .0018, liquid intake: 
F3,29 = 11.78, P = .0011; Tukey's test; Figure 2D,E), but not in mutants 
that received either treatment (P > .05). Together, in a course of the 
development of ALS pathology, FUS-tg-Veh mice showed a decline in 
physiological readouts, which was partially counteracted by all applied 
treatments, and to the greater extend by Neuro-Cells infusion.
3.1.2 | Motor functions
No significant group differences were found in motor tests till sixth 
week of the study, on weeks 1-5 (P > .05; data not shown). At sixth 
week, in the wire test, the number of animals that has fallen from the 
wire was significantly higher in FUS-tg-Veh group than in controls 
(P = .018, Fisher's test; Figure 3A), that was not the case for groups 
of mutants subjected to either treatment (P > .05). In addition, this 
measure was significantly lower in FUS-tg-NC mice than in FUS-tg-
Veh mice (P = .0028, Fisher's test). ANOVA showed significant ef-
fects of genotype and treatment for the latency to fall (F1,89 = 24.52, 
P < .0001 and F3,89 = 2.867, P = .0410), but not for their interaction 
(F3,89 = 1.126, P = .3431) and a significant decrease of this param-
eter in FUS-tg-Veh mice in comparison with WT-Veh mice (P = .011, 
Tukey's test; Figure 3B). No such differences were observed in 
FUS-tg mice that received either treatment (P > .05).
In the pole test, in comparison with WT-Veh animals, the num-
ber of animals with sliding events was significantly higher in FUS-
tg-Veh, FUS-tg-Ril, and FUS-tg-Cel groups (P = .0023, P = .018, and 
P = .001, respectively; Fisher's test; Figure 3C), but not in the FUS-
tg-NC group (P = .38). This measure was significantly smaller in 
the latter group than in FUS-tg-Veh group (P = .0012; Figure 3D). 
There were significant showed significant effects of genotype for 
the latency to descend (F1,77 = 29.03, P < .0001, two-way ANOVA), 
but not for treatment and their interaction (F3,77 = 1.471, P = .2289, 
and F3,77 = 0.1812, P = .9089). This measure was significantly 
shorter in FUS-tg-Veh and FUS-tg-Cel animals than in controls 
(P = .025 and P = .032¸ respectively; Tukey's test; Figure 3F) sug-
gesting sliding of these mice and motor deficits. No such changes 
were shown for FUS-tg-Ril and FUS-tg-NC animals (P = .32 and 
P = .55, respectively).
The number of animals falling off the rotarod test was sig-
nificantly higher in FUS-tg-Veh group than in WT-Veh controls 
(P = .029, Fisher's test; Figure 3E). No such differences were ob-
served in mutants from the treatment groups (P > .05); this param-
eter was significantly lower in FUS-tg-NC mice than in FUS-tg-Veh 
group (P = .0015). ANOVA showed significant effects of genotype 
for the latency to fall in this test (F1,99 = 14.36, P = .0003), but 
not for treatment and their interaction (F3,99 = 1.431, P = .2383, 
and F3,99 = 1.048, P = .3747). A significant decrease in this mea-
sure was found in FUS-tg Veh group as compared to WT-Veh 
group (F3,29 = 7.28, P = .023 Tukey's test; Figure 3F), but not in 
the groups mutants that received either treatment (P > .05). Thus, 
all treatments prevented the occurrence of significant motor de-
cline in FUS-tg mice in comparison with controls, whereas only 
the Neuro-Cells infusion resulted in a significant improvement in 
motor performance in comparison with vehicle-treated mutants. 
While housing on celecoxib-containing food pellets resulted in a 
nonsignificant decrease of body weight in a control group, this fac-
tor has unlikely interfered with the evaluation of ALS syndrome in 
celecoxib-treated mutants, since no differences in behavioral and 
physiological parameters were found between naïve and celecox-
ib-treated controls.
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3.2 | Histological hallmarks of ALS syndrome in 
FUS-tg mice and effects of Neuro-Cells
There was a significant difference group difference in mass of 
the left and right muscle gastrocnemius (F3,29 = 11.30, P = .004, and 
F3,29 = 12.35, P < .001, respectively, one-way ANOVA). In compari-
son with WT-Veh group, FUS-tg-Veh and FUS-tg-Ril mice, but not 
FUS-tg-NC animals, showed a significant decrease in these measures 
(P = .004 and P = .008, P = .002 and P = .0016, P = .273 and P = .3165, 
respectively, Tukey's test; Figure 4A,B). Because FUS-tg-Ril mice 
showed a loss of muscle mass similar to that of FUS-tg-Veh animals, 
further assessment of muscle atrophy using a histological assay was 
carried out FUS-tg-NC mice that were compared against FUS-tg-Veh 
animals. Histological analysis revealed significant atrophy of muscle 
gastrocnemius in FUS-tg-Veh mice (Figure 4C-E). FUS-tg-NC group 
had significantly lower scores of muscle degeneration than FUS-tg-
Veh mice (U = 9.6, P = .037, Mann-Whitney). Thus, muscle atrophy in 
mutants was partly rescued by Neuro-Cells infusion.
Next, we examined the effects of Neuro-Cells administration on 
the motor neuron degeneration at a time corresponding to the onset 
of the ALS syndrome and the muscle atrophy, as mentioned above. At 
this time, there was a significant loss (40%-60%) of motor neurons in 
the FUS-tg mutants.9 FUS-tg-NC group displayed improved motor scores 
in comparison with other groups as well as higher muscle mass as com-
pared to Ril-treated mutants. Thus, motor neuron counts in the lumbar 
L3-L5 mouse spinal cord were studied in FUS-tg mice treated with either 
vehicle or Neuro-Cells. We found that the number of motor neurons in 
the lumbar parts of the spinal cord of FUS-tg-NC animals was significantly 
higher than that of FUS-tg-Veh animals (U = 2.62, P = .039, Figure 4F-H).
3.3 | Pro-inflammatory changes and altered 
activities of GSK-3 in FUS-tg mice: effects of 
celecoxib and Neuro-Cells
There were significant group differences in serum concentrations of 
IL-1β and IL-6 (F = 10.62 P < .001, and F = 11.74, P < .001, one-way 
ANOVA, respectively). In comparison with WT-Veh mice, these meas-
ures were significantly elevated in FUS-tg-Veh group (P = .012 and 
P = .035, respectively; Tukey's test; Figure 5A,B). No such increases 
in IL-6 were found for FUS-tg-Cel and FUS-tg-NC groups (P = .29 and 
P = .22, respectively). These groups showed a significant decrease in 
this measure in comparison with the FUS-tg-Veh mice (P = .01 and 
P = .025, respectively). In comparison with FUS-tg-Veh group, serum 
F I G U R E  2   Effects of riluzole, 
celecoxib, and Neuro-Cells on 
physiological parameters of FUS-tg mice. 
A, There was a significant increase in 
body weight in the WT groups, but not 
in the FUS-tg-Veh mice (*P < .05 vs basal 
values; see the text). FUS-tg mice-NC 
group showed a significant weight gain. 
B, In comparison with controls, there was 
significantly lower weight gain in FUS-tg 
mice except FUS-tg-NC, (*P < .05 vs WT-
Veh group); no such changes were found 
in the FUS-tg-NC group (P > .05). C, At 
Week 6, there was a significant reduction 
of body weight in FUS-tg-Veh group 
in comparison with wild-type controls 
(*P < .05); no such changes were found in 
mutants that received other treatments 
(P > .05). In comparison with WT-Veh 
group, FUS-tg-Veh group displayed a 
significant decrease in (D) liquid intake 
and (E) food intake (*P < .05), but not 
other FUS-tg groups. Each WT-group was 
comprised of 8 animals; 7-11 mice were 
used in FUS-tg groups (FUS-Veh, n = 11; 
FUS-Ril, n = 9, FUS-Cel, n = 7, FUS-NC, 
n = 7)
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levels of IL-1β were significantly lower in FUS-tg-Cel mice and non-
significantly lower in FUS-tg-NC mice (P = .042 and P = .065, respec-
tively; Figure 5A); no other significant differences were found.
Significant group differences in protein levels were found for 
GSK-3β, IL-1β, and Iba-1 (F = 4.992, P = .0035; F = 6.784, P = .0006; 
and F = 5.605, P = .0018) but not GSK-3α (F = 1.359, P = .272). In com-
parison with WT-Veh mice, expression of GSK-3β, IL-1β, and Iba-1, but 
not GSK-3α was significantly elevated in FUS-tg-Veh animals (P = .026, 
P = .013, P = .041, and P = .14, respectively, Tukey's test; Figure 5C-F; 
for original Western blot images used for quantification see Figure S6). 
All increased parameters were significantly lower in FUS-tg-NC mice 
than in the latter group (P = .0027, P = .011, and P = .036, respectively); 
similar decreases were found in FUS-tg-Cel group for IL-1β, but not for 
GSK-3β and Iba-1 (P = .017, P = .181, and P = .785, respectively). Thus, 
both administration of celecoxib and Neuro-Cells decreased, but only 
the latter treatment has significantly lowered expression of markers of 
microglial activation Iba-1 and GSK3β in the spinal cord.
3.4 | Effects of administration of Neuro-Cells 
infusion in SOD-1 mice
There were no significant differences in body weight between 
SOD-1-Veh and SOD-1-NC groups during weeks 1-9 (P > .05; 
F I G U R E  3   Motor parameters in FUS-tg mice and effects of riluzole, celecoxib, or Neuro-Cells. In comparison with WT-Veh mice, FUS-tg-
Veh group showed a significant (A) increase in the number of mice with falling events and (B) decrease in the latency to fall in the wire test, 
that was not found in FUS-tg animals that received either treatment (P > .05). FUS-tg-NC mice had a significantly lower number of mice with 
falling events. In the pole test, in comparison with controls, FUS-tg-Veh, FUS-tg-Ril, FUS-tg-Cel, but not in FUS-tg-NC had a significantly (C) 
higher number of mice with sliding events and (D) decrease in the latency to descend. The latter group had a significantly fewer mice with 
sliding events than the FUS-tg-Veh group. In the rotarod, in comparison with WT-Veh animals, FUS-tg-Veh mice, but not mutant mice that 
received either treatment, had (E) higher number of mice with falling events and (F) a significant decrease in the latency to fall. FUS-tg-NC 
mice had a significantly fewer number of animals displaying falling in comparison with the FUS-tg-Veh group; this group and riluzole-treated 
FUS-tg mice did not show changes in the latency to fall in comparison with the WT-Veh mice (*P < .05 vs WT-Veh group, #P < .05 vs FUS-
tg-Veh group; left panels: exact Fisher's test, right panels: two-way ANOVA and Tukey's test). Each WT-group was comprised of 10 animals; 
7-15 mice were used in FUS-tg groups (FUS-Veh, n = 15; FUS-Ril, n = 10, FUS-Cel, n = 7, FUS-NC, n = 9)
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Mann-Whitney test). The number of mice fallen from the wire was 
significantly lower, and the latency to fall was significantly longer 
in SOD-1-NC than in SOD-1-Veh groups (P = .028, Fisher test; and 
U = 4.5, P = .003; Figure 6A,B). No other group differences were 
found (data not shown). There was a trend to higher muscle weight in 
SOD-1-NC animals in comparison with SOD-1-Veh mice for left and 
right muscles gastrocnemius (U = 6.5, P = .081, and U = 7, P = .10, 
respectively; Figure 6C,D) and an optical trend to higher liquid 
and food intake in SOD-1-NC mice (U = 7, P = .10, U = 3.6, P = .16; 
Figure 6E,F). Thus, Neuro-Cells infusion to SOD-1 mutants resulted 
in overall improved functional readouts in these mice.
4  | DISCUSSION
Our study supports the hypothesis that the new stem cell preparation 
Neuro-Cells ameliorates an experimental ALS syndrome. A single i.c.v. 
infusion of Neuro-Cells into FUS-tg mutants counteracted the develop-
ment of neurodegenerative changes, muscle atrophy, motor deficits, and 
general physical decline and was associated with a decrease in inflam-
matory markers. These findings are in accordance with recently pub-
lished results demonstrating beneficial functional and anti-inflammatory 
action of Neuro-Cells in a rat model of spinal cord injury.23 The effects 
of Neuro-Cells in FUS-tg mice were compared against standard thera-
pies with riluzole and classic anti-inflammatory drug celecoxib. These 
standard treatments partially ameliorated ALS pathology, but these 
improvements were less marked than the effects of Neuro-Cells. The 
administration of Neuro-Cells, but not celecoxib, normalized the expres-
sion of Iba-1, a marker of microglial activation and GSK-3ß expression in 
the spinal cord. While the administration of celecoxib altered cytokine 
expression in the mutants in a similar manner as Neuro-Cells, it did not 
alter the expression of Iba-1 and GSK-3ß in the mutants.
The findings concerning Iba-1 and GSK-3ß expression support the 
view that there is a critical role for microglial activation and inflamma-
tion in ALS.14-18 The upregulation of GSK-3ß cascade is known to be 
functionally associated with pro-inflammatory changes and microglial 
activation, which is a well-established marker of ALS histopathology, 
and the FUS-ALS forms in particular.59,60 GSK-3ß activities are in-
versely related to neurotrophin expression, and its downregulation is 
another recognized molecular feature of human ALS.15,18,61 GSK-3ß is 
also implicated in the mechanisms of microglial activation during neu-
rodegeneration.62 Thus, present study suggests that microglial activa-
tion and increased GSK-3ß activities could be targets for ALS therapy, 
as they were normalized by the administration of the stem cell therapy.
F I G U R E  4   Histological hallmarks of 
ALS-like syndrome in FUS-tg mice treated 
with Neuro-Cells. In comparison with 
WT-Veh, FUS-tg-Veh, FUS-tg-Veh and 
FUS-tg-Ril showed a significant decrease 
in the mass of muscles gastrocnemius 
of (A) left and (B) right limbs (*P < .05 vs 
WT-Veh group) that was not observed for 
FUS-tg-NC group (P > .05; 6-10 mice were 
used: WT-Veh, n = 10, FUS-Veh, n = 10; 
FUS-tg-Ril, n = 8, FUS-tg-NC, n = 6). C, A 
score of atrophy between (D) moderate 
and (E) severe cases (extreme histological 
examples in mice from FUS-tg-NC (n = 5) 
and FUS-tg-Veh (n = 6) groups) revealed 
significantly lower scores for FUS-tg-NC 
than FUS-tg-Veh mice (P* < .05, Mann-
Whitney). F, The number of motor neurons 
was significantly higher in FUS-tg-NC 
of FUS-tg-Veh mice (P* < .05, Mann-
Whitney, 6 mice per group were used). 
H,G, Photomicrographs exemplifying the 
range of motor neuron number in the 
ventral horn of the lumbar cord in FUS-
tg-NC of FUS-tg-Veh mice in lumbar parts 
of the spinal cord, respectively. Scale 
bar = 20 μm
     |  513MUNTER ET al.
It is a generally held view that the anti-inflammatory effects of 
stem cells are considered to be attributable to the paracrine activ-
ity of anti-inflammatory cytokines and growth factors, as well as 
the release of extracellular vesicles containing anti-inflammatory 
and anti-apoptotic proteins.22,63,64 These processes are likely to 
act on RNA-dependent and RNA-independent elements of FUS-
related pathology.6,11,65,66 Transplanted bone marrow derived stem 
cells were shown to secrete such anti-inflammatory cytokines and 
growth factors, as IL-10, vascular endothelial growth factor (VEGF), 
insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), 
brain-derived neurotrophic factor (BDNF), neuronal growth factor 
(NGF), and others.67,68 This secretion was shown to be condition-de-
pendent, and in particular, the presence of inflammation was found 
to stimulate the release of the anti-inflammatory molecules.67 Given 
that FUS protein is considered to be functionally related with insulin/
IGF-signaling pathway,69 an important element of which is BDNF, a 
ligand of TrkB receptor,70 which regulates the mechanisms of cellular 
stress,71,72 it can be suggested that paracrine secretion of Neuro-
Cells cytokines and growth factors may underlie the anti-inflamma-
tory and antidegenerative changes observed in the FUS-tg mice.
In addition, FUS protein can regulate the serine-threonine protein 
kinase (Ak strain transforming, Akt) and forkhead box O1 (FOXO) pro-
teins,58 further elements of GSK-3β cascade that can explain the re-
ported changes in GSK-3β expression in the FUS-tg model. Moreover, 
paracrine secretion by stem cells of trophic factors can ameliorate 
decreased vascular network density in lumbar spinal cords, a recently 
demonstrated disease mechanism in employed here FUS-tg mice, 
which is sensitive to a therapy with angiogenetic/growth factors.73 
Thus, it might be speculated that the effects of the stem cells might 
be due to paracrine activities and the release of neurotrophins and an-
ti-inflammatory cytokines that classical drug therapy cannot provide.22
We found that the physiological parameters and performance of 
FUS-tg mice treated with Neuro-Cells compared to mutants receiving 
other therapies were better preserved. In particular, celecoxib-treated 
mutant mice exhibited limited amelioration of the functional endpoints 
and no changes in the Iba-1 or GSK-3ß expression. These data may go 
some way to explain the reported failures of using anti-inflammatory 
drugs during ALS.19-21 Nevertheless, standard ALS and anti-inflamma-
tory treatment induced partial ameliorative effects on the ALS-related 
abnormalities that validates the FUS-tg line as a model of ALS.
F I G U R E  5   Effects of celecoxib 
and Neuro-Cells on the expression of 
molecular markers of inflammation and 
GSK-3 in FUS-tg mice. A, In comparison 
with controls, animals from FUS-tg-
Veh and FUS-tg-NC groups displayed 
increased serum concentrations of IL-1β; 
FUS-tg-Cel group displayed reduced 
values of this measure in comparison with 
FUS-tg-Veh mice. B, In comparison with 
controls, FUS-tg-Veh, but not FUS-tg-
Cel and FUS-tg-NC, had elevated serum 
IL-6. Two later groups had significantly 
lower serum IL-6 concentrations than 
FUS-tg-Veh group. In comparison with 
WT-Veh mice, there were significantly 
elevated protein levels of (C) GSK-3β, 
(E) IL-1β and (F) Iba-1 in spinal cords of 
FUS-tg-Veh animals; but not in FUS-tg-Cel 
and FUS-tg-NC groups. D, No significant 
differences were found in the protein 
levels of GSK-3α (P > .05). FUS-tg-NC 
group showed significantly lower values 
of protein expression of GSK-3β, IL-1β, and 
Iba-1 than FUS-tg-Veh mice. FUS-tg-Cel 
group showed a significant decrease of IL-
1β expression in comparison to FUS-Veh 
group. (*P < .05 vs WT-Veh group, #P < .05 
vs FUS-tg-Veh group: one-way ANOVA 
and Tukey's test). 5-9 mice per group were 
used: 6 mice in WT-Veh group, 5 mice in 
WT-Cel and FUS-Cel groups, and 9 mice 
in FUS-Veh and FUS-NC groups
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To verify results obtained on FUS-tg mice, we performed the i.c.v. 
infusion of Neuro-Cells in SOD-1 mutants, the classic ALS model. The 
results indicated that there were improved motor functions under 
these conditions following Neuro-Cells administration. Together, our 
data provide evidence of the disease-counteracting and anti-inflam-
matory effects of Neuro-Cells in two experimental models of ALS and 
are in line with previously published reports on effectiveness of stem 
cell therapy during this disease,37,74 as well as with previous findings 
with this preparation applied in a spinal cord injury model.23 They also 
highlight the importance of compliance in preclinical ALS studies with 
the internationally accepted guidelines 24 to more accurately approx-
imate the usefulness of novel therapeutics (see Data S1), including 
stem cells and thus provide a better basis for clinical trials.
5  | CONCLUSIONS
Our study provides the first evidence for greater efficacy of Neuro-
Cells as a therapeutic option capable of counteracting the progres-
sion of ALS-like pathology and accompanying inflammatory changes 
in comparison with the standard pharmacological references. 
As discussed above, it is very likely that both MSCs and HSCs types 
of cells contribute to the effect seen in the study. While beneficial 
effects of HSCs are likely to be due to their well characterized roles in 
neuropoiesis and production of trophic factors, MSCs, besides their 
crucial function in the regulation of HSCs functions, might amelio-
rate angiogenesis and vascular density and exert anti-inflammatory 
effects. Further research is needed to define the mechanisms of anti-
inflammatory action and other effects of Neuro-Cells on hallmarks of 
ALS syndrome. Yet, at this stage, stem cell therapy should be consid-
ered as part of therapeutic approach to the treatment of ALS.
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